source
- Novo Nordisk’s oral Wegovy sales beat forecasts, boosting shares over 5%BioPharma Dive’s latest visualization series examines how investors reacted to three drug launches highlighted in recent quarterly earnings. Novo Nordisk reported that its oral Wegovy generated 5.…
- Medicare to slash 340B drug payments and expand site-neutral rules in 2027Medicare finalized a rule that will cut payments for drugs covered by the 340B discount program and broaden site-neutral payment policies beginning in 2027. The rule is expected to reduce Medicare…